TRANSLATIONAL PATHOLOGY CORE LABORATORY SHARED RESOURCE (TPCL) ABSTRACT The Translational Pathology Core Laboratory (TPCL), a UCLA Jonsson Comprehensive Cancer Center (JCCC) Shared Resource since 1998, provides pathology services critical for basic, translational, clinical, and population cancer research. TPCL provides a College of American Pathologists accredited human tissue biobank, histology (animal/human; frozen/formalin-fixed paraffin embedded), laser capture microdissection, immunohistochemistry and in-situ hybridization services (established/new antibody optimization), and pathology consultation services. TPCL connects cancer researchers with subspecialty pathologists and was an early adopter of digital pathology, assisting with custom digital image analysis algorithms for complex evaluations of tissue sections. TPCL provided essential services and materials for numerous, recent high-impact studies, including work demonstrating that a sodium-glucose transporter is a potential diagnostic and therapeutic target in early-stage lung adenocarcinoma, and that therapy-induced tumor secretomes promote resistance and tumor progression. TPCL supports many clinical trials, including a recent UCLA-led investigator-initiated clinical trial of dual-cell immunotherapy, combining a NY-ESO-1 specific T cell receptor adoptively transferred with NY-ESO-1 peptide- pulsed dendritic cell vaccination, with or without ipilimumab-induced CTLA-4 blockade. During 2013 ? 2018, TPCL developed four-color multiplexed immunofluorescence (MIF) staining for the Leica/Aperio slide scanner, which is a unique scanner capability, introduced nine-color MIF with a Perkin-Elmer Polaris system, created processes to identify and retrieve remnant biofluids with customized clinical variables, initiated a video universal electronic consent for biobanking, built research blood draw order capabilities within routine clinical lab orders, collaborated on a UC Virtual Biobank, and added biofluid acquisition, processing and storage. TPCL fees are similar to or lower than those of other cancer centers within Los Angeles County. During the prior project period, 153 JCCC members from all six Research Programs used TPCL representing 69% of overall usage. Their usage resulted in 334 publications, 49% of which were in high-impact (IF ?10, or field leading) journals. TPCL is centrally located to most JCCC labs and occupies ~6,400 sf. TPCL Director Sarah Dry, MD (ZY), and Co-Directors Samuel French, MD, PhD (ZY) and Dawn Ward, MD, are board-certified, practicing pathologists who conduct basic, translational, and clinical research. Since 2013, Dry co-led the UCLA biobanking consent effort, with 39,700 consents in 24 months, using a novel video e-consent process. Dry also initiated efforts leading to current TPCL collaborations with UC Davis on a University of California (UC) Virtual Biobank. Exciting future TPCL directions to support and benefit JCCC research include: (1) Automated IF/combined IF/RNA-ISH staining; (2) Increased clinical variable searches for remnant biofluids; (3) Facilitated use of research blood draw requests by non-clinicians; and (4) Continued development of the UC Virtual Biobank.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-44
Application #
9936718
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Heard, Jeffrey J; Phung, Ivy; Potes, Mark I et al. (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18:69
Kim, Roy Y; Mangu, Darian; Hoffman, Alexandria S et al. (2018) Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis. Brain 141:132-147
Pothoulakis, Charalabos; Torre-Rojas, Monica; Duran-Padilla, Marco A et al. (2018) CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. Int J Cancer 142:334-346
Montecino-Rodriguez, Encarnacion; Casero, David; Fice, Michael et al. (2018) Differential Expression of PU.1 and Key T Lineage Transcription Factors Distinguishes Fetal and Adult T Cell Development. J Immunol 200:2046-2056
Black, David S; Cole, Steve W; Christodoulou, Georgia et al. (2018) Genomic mechanisms of fatigue in survivors of colorectal cancer. Cancer 124:2637-2644
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Chua, Bernadette Anne; Ngo, Jamie Ann; Situ, Kathy et al. (2018) Protein S and Gas6 induce efferocytosis of HIV-1-infected cells. Virology 515:176-190
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714

Showing the most recent 10 out of 767 publications